1700052N19Rik Activators
1700052N19Rik Activators encompass a diverse set of chemical compounds that facilitate the enhancement of 1700052N19Rik's function through specific signaling pathways. Forskolin works by elevating cAMP in cellular compartments, thereby activating PKA, which can indirectly augment the activity of 1700052N19Rik by phosphorylating proteins within associated signaling pathways. Similarly, A-769662 activates AMPK, which can lead to changes in energy metabolism and subsequent activation of cellular processes that may enhance the activity of 1700052N19Rik. Ionomycin increases intracellular calcium concentrations and activates calcium-dependent signaling that could intersect with 1700052N19Rik's function. The role of PMA as a PKC activator suggests that it may modulate kinase signaling pathways to indirectly increase 1700052N19Rik activity. LY294002, as a PI3K inhibitor, and PD98059, an MEK inhibitor, work through the PI3K/AKT and MAPK/ERK pathways, respectively. Their inhibition can indirectly promote signaling pathways that 1700052N19Rik might be involved in, potentially enhancing its functionality. SB203580's inhibition of p38 MAPK could similarly lead to the activation of alternative pathways, indirectly benefiting 1700052N19Rik's activity.
The modulation of cyclic nucleotide levels by Sildenafil, Zaprinast, and IBMX through the inhibition of phosphodiesterases, leads to an increase in cGMP and cAMP, which in turn can activate signaling mechanisms related to 1700052N19Rik. By elevating cGMP levels, Sildenafil and Zaprinast potentially enhance the activity of 1700052N19Rik by engaging pathways related to cGMP signaling. On the other hand, Sp-8-Br-PET-cGMPs and Dibutyryl cAMP (db-cAMP) act as stable analogs for cGMP and cAMP, respectively, activating PKG and PKA and possibly leading to the enhancement of 1700052N19Rik activity through downstream signaling effects. These activators, each influencing distinct cellular pathways, collectively contribute to the regulation and enhancement of the activity of 1700052N19Rik without directly altering the protein or its expression but by potentiating related signaling processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662 is an AMPK activator. Activation of AMPK can lead to various downstream effects that could overlap with the cellular functions of 1700052N19Rik, potentially enhancing its activity through metabolic modulation. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent proteins and pathways that may indirectly enhance the function of 1700052N19Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator and could affect signaling pathways that overlap with 1700052N19Rik's role, indirectly increasing its activity by modulating related kinase signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and its action can modulate the PI3K/AKT pathway, potentially impacting downstream effects that could lead to the enhancement of 1700052N19Rik activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that can influence the MAPK/ERK pathway. By inhibiting this pathway, the chemical might shift the balance towards other pathways that 1700052N19Rik is a part of, thus indirectly enhancing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38, it may activate alternative signaling pathways or processes that could indirectly enhance the activity of 1700052N19Rik. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another PDE5 inhibitor that raises cGMP levels in cells. This increase might indirectly activate pathways in which 1700052N19Rik is involved, thereby enhancing its functional activity. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
This is a cGMP analog that resists degradation by PDE and can activate PKG. Activation of PKG could potentially alter signaling in a way that indirectly enhances the activity of 1700052N19Rik. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased levels of both cAMP and cGMP, potentially enhancing 1700052N19Rik activity by broadly affecting signaling pathways. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
db-cAMP is a cell-permeable analog of cAMP that activates PKA and can modulate pathways that potentially overlap with the functional activity of 1700052N19Rik. | ||||||